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Abstract
Background: To understand the impact of yet undiagnosed non-radiographic axial spondyloarthritis (nr-axSpA) and
ankylosing spondylitis (AS) on work outcomes in a cohort of patients with long-lasting chronic low back pain (CLBP).
Methods: Data were used from a primary care CLBP cohort that was established to understand the prevalence of nr-
axSpA and AS. Clinical characteristics comprised measures of back pain (visual analogue scale), inflammation (C-reactive
protein) and physical functioning (Roland Morris Disability Questionnaire (RMDQ)). Worker outcomes comprised a
question on employment and the Work Productivity and Activity Impairment (WPAI) questionnaire, distinguishing
absenteeism, presenteeism, and overall work impairment in those employed and activity impairment in all patients. For
each disease subgroup, employment ratio compared to the general population was assessed by indirect standardization.
Factors associated with work productivity were explored by zero inflated negative binomial (ZINB) regression models.
Results: Patients with CLBP (n = 579) were included (41% male, mean age 36 years), of whom 71 (12%) were identified as
having nr-axSpA and 24 (4%) as having AS. The standardized employment ratios were 0.89 (95% CI 0.84–0.94), 0.97 (95%
CI 0.85–1.09) and 0.81 (95% CI 0.56–1.06) for patients with CLBP, nr-axSpA and AS, respectively. Scores for the WPAI
subdomains were not significantly different between patients with CLBP, nr-axSpA or AS. The ZINB models showed
significant associations between visual analog scale (VAS) score for pain and RMDQ and work productivity.
Conclusion: The impact of yet undiagnosed nr-axSpA and AS on patients’ work outcomes was substantial but was not
significantly different from those of patients with long-standing CLBP. Variables significantly associated with reduced work
productivity were VAS for pain and RMDQ score.
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Background
Low back pain (LBP) is a major health and societal prob-
lem affecting more than 80% of adults at some point in
their lives [1]. Between 10 and 28% of episodes of LBP
persist for more than 12 weeks and become chronic com-
plaints [2]. A study has shown that up to 24% of chronic
LBP (CLBP) in young adults can be explained by axial
spondyloarthritis (axSpA) [3]. AxSpA is an auto-
inflammatory disease of the spine that is potentially treat-
able. Two subtypes of axSpA can be distinguished; in non-
radiographic axSpA (nr-axSpA) either sacroiliitis is visible
on magnetic resonance imaging (MRI) or human
leukocyte antigen B27 (HLA-B27) is positive, and in
addition one or two so-called SpA features are present [4].
In those with radiographic axSpA, structural changes are
visible on the X-ray of the sacroiliac joints and this sub-
type corresponds to what is commonly known as ankylos-
ing spondylitis (AS).
Although the new classification criteria for axSpA
were developed to enhance early recognition and subse-
quently provide earlier and better treatment, the profile
of those in whom the diagnosis of axSpA is wrongly
missed is not completely elucidated. This is important,
as it could provide insight into the reversible burden of
the disease when diagnosis would have made earlier.
Several studies report an overall comparable clinical bur-
den in patients with AS and nr-axSpA [5, 6], however
these patients were referred in prospective settings and
not wrongly missed.
The clinical burden of a chronic inflammatory disease
can be expressed in terms of disease activity and im-
paired function, but also in work participation [7]. The
impact of undiagnosed axSpA on the patients’ capacity
to work is important from the perspective of the patient
and their families [8], and from the societal perspective
when calculating indirect costs to determine the eco-
nomic burden of a disease and the possible return on in-
vestment by using case-finding strategies for axSpA
patients. Moreover, such data can help us understand
the level of support patients with axSpA might need to
help them to remain active in the labor force and safe-
guard their career perspective.
Some data are already available on the impact of
AS and axSpA on work participation. A review of
work outcomes in AS indicates that patients with
longstanding disease incur official work disability up
to three times more frequently, and that there had
already been substantial work loss at the time of diag-
nosis [9]. Also a recent study in patients with early
axSpA reported that within only 5 years of diagnosis,
19% of patients with axSpA were not employed be-
cause of the axSpA [10]. Also, in those still working,
28% and 48% of the patients reported having sick
leave and reduced productivity at work [10]. A recent
medication trial in patients with nr-axSpA showed an
improvement in worker productivity of 9.6 h/week in
the patients with nr-axSpA who had a good response
to their treatment (assuming a 40-hour working week)
[11], suggesting that early recognition of axSpA might
prevent adverse work outcomes. It is already known
that CLBP has a significant impact not only on work
productivity, but also on daily activities [12, 13].
The aim of this study was to investigate work out-
comes in yet undiagnosed patients with nr-axSpA and
AS among a cohort of patients with CLBP. The specific
aims were to compare the employment of patients with
AS, nr-axSpA and CLBP with the general population, to
explore whether these diagnostic groups differed in sick
leave and productivity at work and to explore which
demographic and disease characteristics contributed to
sick leave and productivity at work.
Methods
Study population
All patients from the second cross-sectional Case Find-
ing Axial SpondyloArthritis (CaFaSpA 2) study were in-
cluded [14]. The study was performed in 2011 and 2012
in the south-western part of the Netherlands. Ethics ap-
proval from the Medical Ethical Committee from the St.
Elisabeth Hospital in Tilburg, the Netherlands was re-
ceived. Written informed consent was obtained from all
participants at the research center, before any assess-
ment was performed.
Patients with CLBP ages 18-45 years were selected by
ICPC code L03 (nonspecific low back pain) from general
practice (GP) records and invited to participate if the
CLBP had been present for at least 3 months. Participat-
ing patients were examined by a rheumatologist or an
experienced research nurse, i.e. recording of medical his-
tory and physical examination, including identification
of features of SpA. All assessments and definitions ad-
hered to the descriptions in the Assessment of Spondy-
loArthritis International Society (ASAS) handbook [15].
Blood was drawn to determine HLA-B27 positivity, C-
reactive protein (CRP) (normal range 1–10 mg/L) and
erythrocyte sedimentation rate (ESR) (normal range 0–
15 mm Hg/min). X-ray and MRI of the sacroiliac joints
were obtained in all patients. A definitive diagnosis of
sacroiliitis was made according to the ASAS MRI criteria
[4] or the modified New York criteria for the X-ray [16],
by one of three trained radiologists, who were blinded to
the clinical outcomes, laboratory data and results of
other imaging methods. The primary outcome of this
study was to identify new patients with axSpA using the
ASAS classification criteria [4]. None of the newly iden-
tified patients with axSpA had received any treatment
with non-steroidal anti-inflammatory drugs (NSAIDs) or
biologic agents.
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Questionnaires
To assess disease severity patients completed the Bath
AS Disease Activity Index (BASDAI) [17], Ankylosing
Spondylitis Disease Activity Score (ASDAS-CRP) [17], a
visual analog scale (VAS) for pain (range 0–10) and the
Roland Morris Disability Questionnaire (RMDQ) [18].
The RMDQ was developed to measure limitations in
physical functioning in patients with CLBP. It consists of
questions about impairment and limitations in different
activities due LBP. Patients indicate if a question is ap-
plicable to them (score = 1) or not (score = 0). The score
can range from 0 to 24 and a higher score indicates a
higher level of disability.
Socioeconomic status and worker productivity
All participants completed questions about their highest
achieved educational level; low (elementary school),
medium (high school) and high (university), current work
status (employed, or not employed), and the number of
working days and working hours per week in those
employed. To assess whether a patient was work-disabled
or not work-disabled, we asked the patient is there was an
official disapproval of the insurance company doctors. An-
swers to an open question about occupation were classi-
fied into non-manual (administrative, scientific and
managerial professions) and manual (industrial, commer-
cial, servicing, transportation and agricultural) jobs, using
the International Standard Classification of Occupation
(ISCO)-08 major groups [19].
Finally, the Work Productivity and Activity Impair-
ment (WPAI) questionnaire was completed, which eval-
uates four subdomains; absenteeism, presenteeism, work
impairment and activity impairment, due to back prob-
lems in the past 7 days [20]. The subdomains are all
expressed in percentages; absenteeism (percentage work
time lost), presenteeism (percentage productivity loss at
work), work impairment (absenteeism and presenteeism
combined) and activity impairment (percentage activity
loss). Higher percentages indicate worse outcomes.
Statistical analyses
The ASAS criteria were used to classify patients as hav-
ing nr-axSpA, AS or as not fulfilling the criteria (CLBP).
Sociodemographic and clinical characteristics were sum-
marized as mean and standard deviation (SD) or as me-
dian and interquartile range (IQR) and compared
between subgroups using the unpaired t test or Wil-
coxon rank sum test for continuous variables and the
chi-square or Fisher exact test for categorical data.
Indirect standardization (by gender and age categories
of 5 years) was used to calculate employment ratios for
the total population and each disease subgroup (AS, nr-
axSpA and CLBP), in comparison to the general Dutch
population. Employment data from the general Dutch
population was provided by the Dutch Centraal Bureau
voor Statistiek (CBS) [21]. Poisson 95% confidence inter-
vals (CI) for standardized proportions were calculated.
Scores in the WPAI are presented first as the propor-
tion of patients with any (>0%) absenteeism, presentee-
ism, work or activity impairment and next as the average
percentage absenteeism, presenteeism and work and ac-
tivity impairment. Absenteeism, presenteeism and activ-
ity impairment were calculated only in employed
patients, activity impairment in all patients. Differences
between subgroups in the proportions of patients who
had any restriction were tested using the chi-square and
Fisher exact test. Differences between subgroups in the
level of restriction in each subdomain of the WPAI were
tested using the Wilcoxon rank sum test.
To investigate which factors are associated with each
of the four domains of worker productivity, zero inflated
negative binomial (ZINB) models were used. Zero in-
flated models are needed to adjust for the excess zeros
in productivity outcomes (percentage zeros: absenteeism
87%; presenteeism 50%; work impairment 39%; activity
impairment 32% of all observations). ZINB models as-
sume that the zeros can result from two different pro-
cesses; [22] the “certain zeros” (or always zeros) which
are accounted for in the zero inflated logistic part and
the “possible zeros” that are accounted for in the count
part. As in the count part the values are over dispersed
(i.e. the variance was much larger than the mean), the
negative binomial distribution was preferred, and to fit
the four subdomains of the WPAI, zero-inflated models
were used [23].
To create the multivariable ZINB models four different
steps were taken. In step 1 gender and age were included
in both the binomial and count part of the ZINB model.
In the second step all the candidate covariates (disease:
CLBP, nr-axSpA or AS; education level: low, intermedi-
ate, high; occupation: manual vs. non-manual; duration
of LBP (years); VAS score for pain; CRP, RMDQ score,
ASDAS-CRP score and BASDAI score) were tested in
univariate analysis in both the binomial and count part
of the ZINB. All variables that were significant at p <
0.20 were considered for multivariable analyses in step 3.
However, ASDAS-CRP and BASDAI were not validated
in patients with CLBP, and as moderate correlation was
seen between the VAS score for pain and the BASDAI
score it was decided to take the ASDAS-CRP and BAS-
DAI scores out of the multivariable model. In step 4, the
model was repeated with the covariates with p values
<0.05 in the multivariable analysis.
A ZINB provides regression coefficients for both the lo-
gistic and the count part separately. A positive coefficient
in the zero inflated (logistic) part of the ZINB means that
an increase in that variable leads to a higher likelihood of
resulting in a “certain zero”’. A negative coefficient in the
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count part of the ZINB means that an increase of that vari-
able leads to a smaller chance of scoring a zero in the out-
come (i.e. subdomain of the WPAI).
The analyses were performed using STATA version
13.0 software (Stata Corporation TX, USA).
Results
CaFaSpA cohort
The enrollment of patients in the CaFaSpA 2 study has
previously been described [14]. Overall, 2597 patients
(ages 18–45 years) with CLBP from 38 primary care prac-
tices were invited to participate: 1161 patients (45%)
responded to the invitation, among whom 480 expressed
no interest in participation and 102 did not fulfil the inclu-
sion criteria. In total there were 579 patients with CLBP
included in this study. The median duration of LBP was 7
years (IQR 3–15 years), 41% of the patients were male and
the mean age was 36.0 years (SD 7.0) (Table 1). In total 95
patients (16.4%) were classified as having axSpA, and 24
of those (25%) fulfilled the classification criteria for AS
and 71 (75%) for nr-axSpA. The majority (59 out of 71) of
the patients in the nr-axSpA group was classified based on
MRI abnormalities. The percentage of women in the AS
group was higher (75%) compared to the nr-axSpA (58%)
and CLBP group (58%), although this difference was not
statistically significant (p = 0.10). Of the three disease sub-
groups, patients with AS (8%) were less highly educated
compared to patients with CLBP (21%) or nr-axSpA
(24%). The percentage of patients with a manual occupa-
tion in the nr-axSpA group was 46% compared to 29% in
the AS group and 37% in the patients with CLBP.
Work status
In total 342 out of 579 participants (72.4%) were
employed. After adjusting for age, the likelihood of being
employed was 0.92 (95% CI 0.86–0.99) and 0.88 (95%CI
0.81–0.94) for men and women, respectively, compared
with the Dutch general population. Age-adjusted ratios
for being employed, in patients with CLBP, nr-axSpA or
AS were 0.89 (95% CI 0.84–0.94), 0.97 (95% CI 0.85–
1.09) and 0.81 (95% CI 0.56–1.06), respectively. There
were no patients with a disability pension in the newly
identified AS group, while there were eight patients
(1.7%) in the CLBP group and two patients (2.8%) in the
newly identified nr-axSpA group.
WPAI questionnaire
Of the 342 employed patients with CLBP, 318 (93%)
completed the WPAI questionnaire, compared to 14/15
patients with AS (93%) and 48/55 patients with nr-
axSpA (87%). Of the employed patients with AS, 14%
had been absent from work in the past 7 days, while this
percentage was 10% and 12% in the employed patients
with nr-axSpA and with CLBP, respectively (Table 2).
Presenteeism was the most prevalent in patients with
CLBP (59%), but the percentage presenteeism was the
highest in the AS group at 59%. There were no signifi-
cant differences in any of the four sub scores between
patients with CLBP and patients with nr-axSpA, or be-
tween patients with CLBP and patients with AS.
ZINB models
Detailed results on the age-adjusted and gender-adjusted
univariable regression can be found in Additional file 1,
while the final multivariable model is presented in
Table 3. In the final model the VAS score for pain and
the RMDQ score were independently associated with
the logistic part of each of the four domains of the
WPAI. For the count part of the model, the VAS score
for pain and the RMDQ score were independently asso-
ciated with presenteeism, and work and activity impair-
ment. This means that patients with pain and functional
limitations are unlikely to have no restrictions in worker
Table 1 Demographics and clinical characteristics in study







Age, mean (SD) yearsa 35.6 (7.1) 36.8 (6.6) 38.6 (5.8)
Male sex, n (%) 202 (42) 30 (42) 6 (25)
LBP duration, mean (SD) years 9.2 (7.7) 9.6 (7.4) 9.3 (9.9)
Disease activity
VAS pain, median (IQR)b 5 (3–7) 4 (2–5) 4.5 (2–7)
BASDAI, median (IQR) 4.2 (2.3–6) 3.9 (2.4–5.4) 5.3 (2.9–6.6)
ASDAS-CRP, median (IQR)c 2.3 (1.6–2.9) 2.3 (1.6–2.9) 2.8 (2.1–3.5)
RMDQ, median (IQR)d 7 (3–13) 6 (3–9) 12 (5–17)
Educational levele
Low (elementary school) (%) 177 (38) 29 (41) 11 (46)
Medium (high school) (%) 194 (41) 24 (34) 11 (46)
High (university) (%) 101 (21) 17 (24) 2 (8)
Work status
Employed, n (%) 342 (72.2) 55 (77.5) 15 (62.5)
Disability pension, n (%) 8 (1.7) 2 (2.8) 0 (0)
Number of hours working
per week, mean (SD)f
33.1 (9.4) 34.6 (8.6) 27.9 (12.4)
Occupation in employed patientsf
Manual, n (%) 124 (37) 24 (46) 4 (29)
Non-manual, n (%) 208 (63) 28 (54) 10 (71)
CLBP chronic low back pain, Nr-axSpA non-radiographic axial spondyloarthritis,
AS ankylosing spondylitis, IQR interquartile range, LBP low back pain, VAS visual
analog scale, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
ASDAS-CRP Ankylosing Spondylitis Disease Activity Score-C-reactive protein,
RMDQ Rolland Morris Disability Questionnaire. ap = 0.04 for CLBP vs. AS; bp =
0.04 for CLBP vs. nr-axSpA; cp = 0.01 for CLBP vs. AS; dp = 0.03 for CLBP vs. AS;
etotal number of questionnaires about educational level: CLBP, n = 472 (12
missing), nr-axSpA, n = 70 (1 missing); ftotal number of questionnaires about
occupation and working hours in employed patients: CLBP, n = 332 (10
missing), AS, n = 14 (1 missing), nr-axSpA, n = 52 (3 missing)
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productivity (so unlikely to belong to the zero inflated
part) and that increased pain and functional limitations
are associated with more presenteeism, overall work im-
pairment and activity impairment, but no absenteeism.
In addition, lower educational level was associated with
a likelihood of work impairment and level of overall
work impairment, and with the level of presenteeism,
and longer disease duration was associated with a de-
creased likelihood of work impairment.
As an example of the interpretation of the output of the
ZINB model; for activity impairment the “inflated” (logit)
model predicting the “certain zeros” indicates that if a pa-
tient was to increase their VAS pain score by one point,
the odds that the patient will belong in the “certain zero”
group (have no activity impairment) would be a factor of
exp(-0.261) = 0.770. In other words, the higher a patient’s
VAS score the less likely the patient is to be a certain zero
(have no activity impairment). On the other hand, the
“count” part indicates that one point increase in the VAS
pain score would increase activity impairment by a factor
exp(0.079) = 1.082. Thus, the higher a patient’s VAS score,
the more activity impairment is present.
Discussion
To our knowledge this is the first study investigating the
impact of yet undiagnosed nr-axSpA and AS on work out-
comes within a group of patients with long-standing CLBP.
The employment rate among our patients with CLBP was,
as anticipated, lower than expected compared to the Dutch
population of the same age and gender, and the lower em-
ployment rate was more pronounced in the patients with
AS, although this was not significantly different. In addition
the patients with AS reported the highest values of absen-
teeism, presenteeism and work and activity impairment, al-
though the differences between patients with CLBP and nr-
axSpA were not significant, perhaps due to the small
Table 2 Worker productivity assessed by the WPAI for employed patients with CLBP, nr-axSpA or AS (18–45 years of age)
CLBP (n = 318) Nr-axSpA (n = 48) AS (n = 14)
Absenteeism
Absenteeism present, n (% (95% CI)) 38 (12 (8–16)) 5 (10 (4–23)) 2 (14 (2–43))
Absenteeism, mean % (SD) 53 (31) 47 (43) 54 (59)
Presenteeism
Presenteeism present, n (% (95% CI)) 188 (59 (53–64)) 23 (47 (34–61)) 7 (53 (27–79))
Presenteeism, mean % (SD) 45 (28) 46 (32) 59 (34)
Work impairment
Work impairment present, n (% (95% CI)) 197 (62 (56–67)) 25 (52 (37–67)) 8 (57 (29–82))
Work impairment, mean % (SD) 49 (30) 48 (33) 62 (36)
Activity impairmenta
Activity impairment present, n (% (95% CI)) 322 (68 (63–72)) 45 (63 (51–75)) 19 (79 (58–93))
Activity impairment, mean % (SD) 51 (27) 49 (28) 56 (34)
WPAI Worker Productivity and Activity Impairment Questionnaire, CLBP chronic low back pain, nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing
spondylitis. There were no significant differences in any of the four sub scores between patients with CLBP and patients with nr-axSpA, or between patients with
CLBP and patients with AS. aCalculated in all patients, not only in the employed patients (CLBP, n = 474; nr-axSpA, n = 71; AS, n = 24)
Table 3 Final results of the ZINB regression model testing associations between demographical and clinical parameters and the
WPAI subdomains corrected for age and gender
Absenteeism Presenteeism Work impairment Activity impairment
Parameter Count Logistic Count Logistic Count Logistic Count Logistic
Education level
Intermediate 0.100 (0.195) -0.051 (0.578) 0.844 (0.004)
High -0.228 (0.015) -0.252 (0.017) 0.716 (0.029)
Duration of LBP (years) 0.043 (0.012)
VAS pain -0.190 (0.008) 0.081 (0.000) -0.165 (<0.001) 0.079 (<0.001) -0.324 (<0.001) 0.079 (<0.001) -0.261 (<0.001)
RMDQ -0.188 (<0.001) 0.048 (<0.001) -0.005 (0.744) 0.058 (<0.001) -0.152 (<0.001) 0.044 (<0.001) -0.106 (<0.001)
Only the significant regression coefficients are shown, with the p values in parentheses. The logistic part of the ZINB model is generated for the “certain zero”
cases, predicting whether or not a patient would be in this group. At the same time the count part of the model is predicting the counts for those patients who
are not certain zeros.
ZINB zero inflated negative binomial, WPAI Worker Productivity and Activity Impairment Questionnaire, LBP low back pain, VAS = visual analog scale, RDMQ Roland
Morris Disability Questionnaire
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number of patients with AS in the study population. Pain
and functional limitations were associated with higher like-
lihood of having any work impairment. Pain by itself was
associated with level of presenteeism, overall work impair-
ment and activity impairment.
A comprehensive comparison with the existing litera-
ture is difficult as this is the first study addressing patients
with previously unrecognized axSpA. Further, there is only
limited literature on work outcomes in patients with nr-
axSpA [24], and last but not least, data on employment
and sick leave are country-specific, as the socioeconomic
environment plays an important role [25]. Notwithstand-
ing, a comparison that can be made involves a recent
study in Dutch patients with early axSpA (defined based
on the ESSG criteria), which evaluated problems in work
participation. This study showed a remarkable high per-
centage of employed patients with axSpA, namely 81%
[10]. This employment rate is even higher than the em-
ployment rate of the Dutch general population in 2014,
which was 74.8% in the age category of 15–45 years [21].
An explanation of this high employment rate can be the
high percentage of male participants in this study, which
was 69% or the relatively low median BASDAI score (3.0)
that was reported by the participants.
Focusing on the variables that are associated with
work productivity in patients with axSpA, they are re-
ported equally within different studies and settings. Sev-
eral studies reported that variables measuring pain,
disease activity and physical functioning are associated
with reduced work productivity [10, 26–29]. This associ-
ation is not only found in axSpA but also in other
rheumatic conditions such as rheumatoid arthritis [30].
The strength of this study is our study population,
which provided an unique opportunity to investigate
work outcomes in as yet undiagnosed patients with nr-
axSpA and with AS and to compare the findings with
those in patients with long-standing CLBP. Moreover,
none of the patients with nr-axSpA or AS had been di-
agnosed or treated by a rheumatologist for their disease,
so there was no treatment bias in assessing the impact
of the disease on work outcomes. A further strength of
this study is the use of the ZINB models to assess associ-
ations with work productivity; this is a very elegant stat-
istical technique using a logistic and a count model at
the same time, creating an optimal fit for our data with
excessive zeros [23].
A limitation of our study is the cross-sectional design,
which limits any conclusions about causality. The risk of
sampling bias was minimized by using only simple inclu-
sion criteria (age 18–45 years and CLBP lasting more
than 3 months). We did not include coping in our ana-
lyses, therefore is it unclear to which extent coping plays
a role in the self-reported questionnaires such as the
VAS for pain and the RMDQ. Not all participants
answered the questions on work outcomes; however, the
response rate for those questionnaires was 92% and
there were no difference in patients’ characteristics be-
tween the responders and non-responders. Another po-
tential limitation is that it is unclear why the patients
with nr-axSpA or AS have not been recognized by their
primary care physicians and referred to a rheumatolo-
gist; is this because their primary care physician had lim-
ited knowledge about axSpA and did not recognize
those patients or because the patients had so far experi-
enced few symptoms from their disease? The second
reason seems unlikely, as the median BASDAI score was
3.9 and 5.2 in patients with nr-axSpA and AS, respect-
ively. Also, selection bias towards more patients with
more severe CLBP seems unlikely, as the median VAS
score in our study is comparable to or even lower than
VAS scores in other cohorts with low back pain [31]. Fi-
nally, the group of patients with AS only contained 24
patients, of whom only 15 were employed, making it
hard to find significant differences between the AS, nr-
axSpA and CLBP groups.
On this line it should be noted that there was a high
percentage women in our AS sample (75%); no other AS
cohorts are reported to have such a high percentage. A
possible explanation can be that we used a different ap-
proach to including patients in our study; we only selected
based on age and the presence of CLBP. In other cohorts
patients have been selected by predefined features specific
to axSpA, leading to the possibility that male participants
are easier to include. On the other hand, this finding could
be an indication that at this moment more female patients
with AS are being missed by primary care physicians, indi-
cating an opportunity to educate primary care physicians
more thoroughly about axSpA.
It is important to conduct research on work productiv-
ity, absenteeism and presenteeism in as yet undiagnosed
patients with axSpA, as they can be indicators of future
work disability [32]. Our results show that there are sig-
nificant associations between patient-reported outcome
measurement (PROMs) such as pain and functional lim-
itations and work productivity, but no associations be-
tween more objective variables such as age, gender,
disease (CLBP, nr-axSpA or AS), manual occupation and
work productivity; this leads to the cautious conclusion
that the impact on work productivity is not disease-
related but related to the degree of pain and physical
limitations a patients experiences. This finding is en-
couraging as we know from previous studies that ad-
equately treating patients with AS or nr-axSpA leads to
an improvement in PROMs [33]. Moreover, after starting
treatment, not only is an improvement in work partici-
pation reported, but also an improvement in unpaid
work is reported in patients with AS and with nr-axSpA
[11, 34]. A recent study in southern Sweden in patients
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with nr-axSpA showed a sustained improvement in work
disability even two years after the start of treatment [35].
These findings emphasize that is important and useful
to recognize patients suspected of having axSpA early
and refer them to a rheumatologist.
Conclusions
Our findings demonstrate that the impact of as yet un-
diagnosed nr-axSpA and AS is substantial although the
outcomes in work productivity were not significantly dif-
ferent from those in patients with long-standing CLBP.
Variables associated with reduced work productivity
were mainly PROMs such as VAS pain score and func-
tional limitations measured by the RMDQ. Early recog-
nition and subsequently adequate treatment of yet
undiagnosed patients with nr-axSpA and with AS can
potentially lead to maintaining optimal work productiv-
ity in patients with nr-axSpA and with AS and a reduc-
tion in indirect costs.
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